Stanton L. Gerson, M.D.
Professor of Hematology and Oncology, Director of Cancer Center
Case Western Reserve University
10900 Euclid Ave.
Cleveland, Ohio 44106
Phone: (216) 844-8565
Dr. Gerson's laboratory's long-standing interest is in evaluating the role of the DNA repair protein O6 alkyguanine-DNA alkyltransferase. One focus is its role in tumor drug resistance to nitrosoureas. He has been a leader in the discovery and development of the AGT modulator O6 benzylguanine. He has demonstrated the efficacy of O6 benzylguanine as a modulator in colon and breast cancer models. This observation has now been extended to a variety of other tumor types and has recently led to the introduction of O6 benzylguanine to the clinic as a modulator of AGT-directed DNA repair. The second focus is in gene therapy using AGT overexpression to protect bone marrow from chemotherapy; a clinical gene therapy is now underway. With Dr. Lili Liu, he has evaluated methoxyamino, an inhibitor of base excision repair, as a potentiator of methylating agent chemotherapy. Dr. Gerson plays an active role in the development of new therapeutics as the Associate Director for Clinical Research.
Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning Journal of Clinical Investigation 112 (10):1561-1570 11/2003.
Zielske SP, Reese JS, Gerson SL Limited Lentiviral Transgene Expression with Increasing Copy Number in an MGMT Selection Model: Lack of Copy Number Selection by Drug Treatment. Molecular Therapy 9 (6): 923-931, 6/04.
Gerson, SL MGMT: Its role in Cancer Aetiology and Cancer Therapeutics. Nature Rev Cancer 4(4) 296-307.